KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
18 hedge funds and large institutions have $52.2M invested in KalVista Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 2 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
3.57% more ownership
Funds ownership: 75.89% → 79.46% (+3.6%)
0% more funds holding
Funds holding: 18 → 18 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
3% less capital invested
Capital invested by funds: $54.1M → $52.2M (-$1.84M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$2.14M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$1.47M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$134K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$11.9K |
| 5 |
BlackRock
New York
|
+$2.85K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$1.26M |
| 2 |
FQ
First Quadrant
Glendale,
California
|
-$11.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$11K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$7K |
| 5 |
Morgan Stanley
New York
|
-$1.13K |
KALV Hedge Fund Activity: Q3 2017 in Review
18 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q3 2017, worth a combined $52.2M — down 3.4% from $54.1M a quarter earlier.
Fund positioning in KALV was balanced in Q3 2017: 2 funds opened new positions, 2 closed out, 5 added to existing stakes and 4 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $2.14M. The largest seller was Novo Holdings A/S, cutting an estimated $1.26M.
- 18 institutional investors held KalVista Pharmaceuticals (KALV) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $52.2M of KalVista Pharmaceuticals stock for Q3 2017, down 3.4% quarter-over-quarter.
- 2 funds opened new KalVista Pharmaceuticals positions in Q3 2017 and 2 closed out, a net change of 0 holders.
- The largest KalVista Pharmaceuticals buyer in Q3 2017 was Vivo Capital, an estimated $2.14M added.
- The largest KalVista Pharmaceuticals seller in Q3 2017 was Novo Holdings A/S, an estimated $1.26M sold.
Based on aggregated 13F filings for Q3 2017.